Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076)

Elizabeth E Tolley1,§, Sue Li2, Sahar Z Zangeneh2, Millicent Atujuna3, Petina Musara4, Jessica Justman5, Subash Pathak2, Linda-Gail Bekker3, Shobha Swaminathan6, Jill Stanton1, Jennifer Farrior1 and Nirupama Sista1

§ Correspondence author: Elizabeth E Tolley, FHI 360, 329 Blackwell Street, Suite 200, Durham, North Carolina 27701. Tel: (001) 919-544-7040 ext 11334. (btolley@fhi360.org)
ClinicalTrials.gov Identifier: NCT02165202.

Abstract
Introduction: High HIV incidence and low adherence to daily oral PrEP among women underscore the need for more acceptable and easier to use HIV prevention products. Global demand for injectable contraception suggests that new, long-acting, injectable formulations could meet this need. We examine acceptability of a long-acting injectable PrEP among HIV-uninfected women in Zimbabwe, South Africa and two United States phase 2 trial sites.

Methods: Quantitative surveys were administered at the first, fourth and sixth injection visits. Focus group discussions (FGD) were conducted after the sixth injection visit. We compared the acceptability of injectable product attributes, prevention preferences and future interest in injectable PrEP by site and arm and ran longitudinal ordinal logistic regression models to identify determinants of future interest in injectable PrEP.

Results: Between April 2015 and February 2017, the trial enrolled 136 (100 African, 36 US) women with a median age of 31 years. Most participants (>75%) rated injectable attributes as very acceptable. While few reported rash or other side effects, 56% to 67% reported injection pain, with nonsignificant differences over time and between arms. During FGDs, participants described initial fear of the injectable and variable experiences with pain. Most US and African participants preferred injectable PrEP to daily oral pills (56% to 96% vs. 4% to 25%). Future interest in using injectable PrEP was associated with acceptability of product attributes and was higher in African than US sites. In FGDs, participants described multiple reasons for trial participation, including a combination of monetary, health-related and altruistic motivations. While associated with future interest in use in univariate models, neither altruistic nor personal motivations remained significant in the multivariate model.

Conclusions: This study found that long-acting injectable PrEP is acceptable among African and US women experiencing product use. Acceptability of product attributes better predicted future interest in injectable use than experience of pain. This is reassuring as a single-dose regimen of a different product has advanced to phase 3 trials. Finally, the study suggests that future demand for an injectable PrEP by women may be greater in African than US settings, where the risk of HIV is highest.

Keywords: HIV prevention; clinical trial; acceptability; PrEP; injectable; women

1 INTRODUCTION

Globally, women account for almost half of the approximately 37 million people living with HIV/AIDS, ranging from 19% of new infections in the US to almost 60% in sub-Saharan Africa (SSA) [1]. While oral PrEP has demonstrated efficacy in women and is approved for use in the US and many countries in SSA, uptake remains low. Lack of awareness, low HIV risk perception and concerns about or challenges taking daily oral pills are key factors undermining use [2–6]. The need for new HIV prevention methods that women find acceptable and easy to use continues to be pressing.
level of adherence achieved within the trial, rather than mode of transmission, sex of participant, PrEP regimens or dosing schemes was the primary moderator of PrEP effectiveness.

Although adherence is likely the key to achieving ARV-based PrEP effectiveness, determinants of adherence have varied for different populations. Two large Phase 3 PrEP trials conducted with heterosexual African women failed to demonstrate effectiveness. In both trials, product adherence was low – especially in younger women, under the age of 25 [13–15]. While reporting moderate levels of effectiveness, two recent trials of PrEP vaginal rings noted similar challenges [16,17]. The wide variations in adherence achieved by women in different PrEP trials have been attributed to various factors including participants’ level of perceived HIV risk, the acceptability of product-related attributes, women’s ability to disclose product use and/or trial participation to sexual partners or others, and their underlying motivations for trial participation [18–20].

Early findings from PrEP demonstration studies suggest that adherence to PrEP regimens may be easier when taking a product of known effectiveness [21,22]. Nevertheless, contraceptive research supports the notion that women’s preferences for method-specific prevention strategies vary widely and adherence-related challenges will differ by product [23]. Continuing high HIV incidence among young women – especially in Sub-Saharan Africa – and strong global demand for injectable contraception [24] suggest that newer, longer-acting injectable (LAI) PrEP may help women meet this need for protection.

HPTN 076 was one of two Phase 2 trials testing the safety and tolerability of a LAI PrEP formulation. This randomized, controlled trial took place between April 2015 and February 2017 and compared the safety of TMC278 LA (rilpivirine) to inactive placebo administered every eight weeks over a forty-week period for a total of six injections. The HPTN 076 trial provided an opportunity to examine and compare acceptability of a LAI PrEP product among HIV-uninfected, low-risk women, aged 18 to 45 years old, across four settings in Africa and the United States – Harare, Zimbabwe; Cape Town, South Africa; Newark, New Jersey and Bronx, New York.

In this study, we assessed acceptability within a multidimensional framework, determined not only by users’ perceptions of product attributes (e.g. location, size, number and frequency of injections), but also the perceived need for HIV prevention and product-specific preferences outside of a trial context. We further theorized that women’s motivations for trial participation might lead them to join trials without a strong interest in using prevention in the future, and that product-related preferences would be influenced by women’s familiarity with different product modalities.

2 | METHODS

Two types of data were collected to assess acceptability of TMC 278 LA. As part of their routine visits, all trial participants were administered quantitative surveys at enrolment, and after the first, fourth and sixth injection visits. In addition, a subset of participants from each site were invited to participate in one of three focus group discussions (FGDs).

2.1 | Quantitative survey measures

Enrolment acceptability measures, collected at baseline only, examined women’s previous use of injections for contraception or other prevention/treatment purposes, HIV risk perception, past HIV prevention behaviours and initial preferences for future HIV prevention product use. We assessed women’s motivations for trial participation based on how important specific reasons were (1 = not at all important to 6 = very important) for joining the trial, including the ‘desire to help scientists find new HIV prevention methods’ and ‘access to medical tests and procedures.’ Similarly, acceptability of five product attributes and three physical experiences were measured on a scale of 1 = highly unacceptable to 6 = highly acceptable after the first, fourth and sixth injection. Product attributes included: receiving two injections at a visit; size/quantity of each injection; receiving injections every two months; injection site in the buttocks and degree of privacy. Physical experiences included: any pain at injection site; any rash/reaction at injection site; and any side effects experienced since last injection. If participants did not experience any pain, rash/reaction or side effects, their response was coded as 6 = highly acceptable.

We conducted separate principal component analyses (PCA) with varimax rotation on the set of seven items describing motivations for trial participation and the eight items describing acceptability of “injectable attributes” and “physical experiences.” The PCA of trial motivations showed two distinct PCs where the first PC comprised three items denoting “altruism” and the second PC comprised four items describing “personal and health benefits.” Similarly, two distinct PCs were found in the PCA of acceptability where the first PC comprised five product acceptability items denoted as “injectable attributes” and the second PC comprised three items denoted as “physical experiences.” The scores for each of the four PCs were calculated as weighted sums of measures of their components with weights $\left(\sum W_i\right)$, where $W_i$ were the loadings from the principal component analysis. The ranges of scores were the same as the ranges of the measures of components [1–6].

In addition to participants’ subjective attitudes towards physical experiences, injection site reactions (ISR) were recorded on an adverse event log by clinical staff at any clinic visit, when observed. We included a count variable for the total number of ISRs, regardless of grade, in our model. Finally, two outcome variables were considered for this analysis. The first assessed participants’ HIV prevention preferences; options included oral PrEP, vaginal rings or gel, and injectables or no preference. We also measured participants’ level of agreement to six statements to assess “future interest in injectable PrEP” (FIIP). HIV prevention preferences and FIIP were measured after the fourth and sixth injection visit. We used the most extreme, positive statement of the six. “You would definitely use the injection for some time” as our primary dependent variable.

2.2 | Quantitative analyses

We compared baseline socio-demographic and risk characteristics between US and Africa sites using Chi-square or Fisher’s Exact tests for categorical variables and t-tests for continuous variables. For prevention preferences, we compared the
proportions of US versus Africa participants who preferred various prevention products within each visit (baseline and Week 28) and between two visits within US sites and Africa sites using Fisher’s Exact test.

We performed univariate and multivariate analyses using a longitudinal ordinal logistic regression model to identify determinants of FIIP. We considered the binary baseline covariates of “Ever injectable contraception,” “HIV risk perception” and two composite variables representing altruistic and personal motivations for trial participation. We also included numeric time-varying covariates describing “Level of condom use last month” and summary scores describing acceptability of “injectable attributes” and “physical experiences.” Treatment arm and site (US vs. African) were also included in the model. The models were fit via generalized estimating equations (GEE), assuming an independence covariance structure [25], using Proc Genmod procedure in SAS. All analyses were implemented using SAS software (version 9.4).

2.3 | Sensitivity analyses

Prior to final selection of our primary outcome variable, “Future interest in injectable PrEP” (FIIP), we fit a model with the positive statement, “You would definitely use the injection for some time” and then conducted a sensitivity analysis using the negative statement “You would not use the injection.” Because results from both regression models were qualitatively similar, we used the positive statement, measured at week 44. In addition, we examined the association between permanent product discontinuation (binary, time-varying) and FIIP, using the same univariate modelling approach described above, to assess whether women who discontinued product use during the trial may have had lower acceptability than women who continued use.

2.4 | Qualitative FGDs

Women still in follow-up between weeks 44 and 76 were invited to participate in an FGD after moving off active product use. Three FGDs were conducted, one each in Cape Town, Harare and New York/New Jersey, with eight to 12 participants per FGD who were selected from a list of randomly sampled participant identification numbers provided to each site. The FGD explored the perceived need for an injectable HIV prevention method; trial and product-related experiences, including the impact of partners, family members and others; and future interest in injectable PrEP. FGDs were conducted in the local language by interviewers trained in open-ended interviewing techniques. The audio-recordings were transcribed, translated into English and typed into word documents for analysis.

2.5 | Qualitative analyses

We imported the FGD transcripts into NVivo version 10. Data were analysed by a team of two qualitative analysts who independently read the first transcript to identify emergent themes. They discussed and agreed on a simple codebook to identify thematic content related to HIV risk perception, motivations for and experiences with trial participation, attitudes towards injectable attributes, and perspectives on who might use an injectable and why. Subsequently the second analyst applied the codes, and both analysts developed thematic memos and data matrices [26] to identify and compare product and trial-related attitudes and experiences across sites. The team reviewed and discussed these analytic products to ensure they had similar interpretations of the data. We incorporated the qualitative data to shed additional light on the survey findings.

2.6 | Ethical statement

HPTN 076 was reviewed and approved by national and local ethics review committees in each site. All participants provided voluntary written informed consent to participate in the trial; FGD participants provided separate informed consent for this activity.

3 | RESULTS

The study enrolled 136 women (100 African, 36 US) with a median age of 31 years. Approximately half of participants were married, with the Zimbabwe site contributing most to this group. Two-thirds of African participants and about half of US participants were unemployed. At baseline, more than half (57%) of participants in the African sites and 47% in the US sites reported ever using injectable contraception and just over half of ever users reported currently using injectable contraception (Table 1).

3.1 | Perceived risk of HIV

Perceived HIV risk differed significantly by region. More than a third of African participants, but just over 10% of US women, were very worried about HIV (p = 0.015). At baseline, most participants did something to reduce HIV risk, including having sex with only one partner (Africa vs. US, 83% vs. 50%, p < 0.001) and condom use (84%) – although only 31% overall said they always used condoms.

At exit, FGD participants continued to describe varying levels of perceived HIV risk. In Cape Town, participants felt that communities were less concerned about acquiring HIV than in the past, whereas in Harare, both knowledge and perceived risk were described as having increased.

Haysuka! I don’t care about that (HIV), We will all have it; we’ll just go to the clinic and take our pills. It’s not a dog’s disease; it’s everyone’s disease. Participant, Cape Town

US participants believed the risk was high, but that people were careless.

It is a big concern, and I am actually afraid of the young people, because they are a little careless right now on a whole. I think they were born knowing about HIV and being a part of their lives. Not giving it much importance, as they should. They are not recognizing how serious this disease is. Participant, US

3.2 | Acceptability of injectable attributes

Although US participants reported lower acceptability of injectable attributes than did women from African sites, most
Table 1. Baseline socio-demographic & risk characteristics

|                                | Overall (n = 136) | US (n = 36) | Africa (n = 100) | p-values |
|--------------------------------|------------------|-------------|------------------|----------|
| Arms assigned                  |                  |             |                  |          |
| Placebo                        | 33% (45/136)     | 33% (12/36) | 33% (33/100)     | n/a      |
| Active                         | 67% (91/136)     | 67% (24/36) | 67% (67/100)     |          |
| Age                            |                  |             |                  |          |
| Mean                           | 31               | 33          | 31               | 0.20     |
| Median (Q1, Q3)                | 31 (25, 38)      | 32 (28, 40) | 31 (24, 37)      |          |
| Marital status                 |                  |             |                  |          |
| Married/civil union            | 46% (63/136)     | 19% (7/36)  | 56% (56/100)     | <0.001   |
| Living with primary partner    | 5% (7/136)       | 19% (7/36)  | 0% (0/100)       |          |
| Primary partner, not living together | 15% (21/136)   | 0% (0/36)   | 21% (21/100)     |          |
| Single/divorced/widowed        | 33% (45/136)     | 61% (22/36) | 23% (23/100)     |          |
| Race                           |                  |             |                  |          |
| Asian                          | 1% (1/136)       | 3% (1/36)   | 0% (0/100)       | <0.001   |
| Black/African American         | 94% (128/136)    | 78% (28/36) | 100% (100/100)   |          |
| Multiracial                    | 1% (1/136)       | 3% (1/36)   | 0% (0/100)       |          |
| Other                          | 2% (3/136)       | 8% (3/36)   | 0% (0/100)       |          |
| White                          | 2% (3/136)       | 8% (3/36)   | 0% (0/100)       |          |
| Employment status              |                  |             |                  |          |
| Full-time employment           | 17% (23/136)     | 33% (12/36) | 11% (11/100)     | 0.009    |
| Part-time employment           | 23% (31/136)     | 19% (7/36)  | 24% (24/100)     |          |
| Not employed                   | 60% (82/136)     | 47% (17/36) | 65% (65/100)     |          |
| Personal benefits score        |                  |             |                  |          |
| Number of non-missing values   | 136              | 36          | 100              | 0.001    |
| Mean                           | 4.8              | 4.2         | 5.0              |          |
| SD                             | 1.2              | 1.2         | 1.2              |          |
| Min, Max                       | 1.7, 6.0         | 2.0, 6.0    | 1.7, 6.0         |          |
| Altruism score                 |                  |             |                  |          |
| Number of non-missing values   | 135              | 36          | 99               | <0.001   |
| Mean                           | 5.9              | 5.6         | 6.0              |          |
| SD                             | 0.3              | 0.5         | 0.2              |          |
| Min, Max                       | 4.1, 6.0         | 4.1, 6.0    | 4.6, 6.0         |          |
| Ever injectable contraception use |            |             |                  |          |
| Yes                            | 54% (74/136)     | 47% (17/36) | 57% (57/100)     | 0.31     |
| No                             | 46% (62/136)     | 53% (19/36) | 43% (43/100)     |          |
| Current injectable contraception use |        |             |                  |          |
| Yes                            | 53% (39/74)      | 53% (9/17)  | 53% (30/57)      | 0.90     |
| No                             | 47% (35/74)      | 47% (8/17)  | 47% (27/57)      |          |
| Level of condom use last month |                  |             |                  |          |
| Did not have sex in past month | 15% (21/136)     | 42% (15/36) | 6% (6/100)       | <0.001   |
| Never                          | 18% (24/136)     | 22% (8/36)  | 16% (16/100)     |          |
| Rarely                         | 9% (12/136)      | 3% (1/36)   | 11% (11/100)     |          |
| Sometimes                      | 18% (24/136)     | 8% (3/36)   | 21% (21/100)     |          |
| Frequently                     | 10% (13/136)     | 3% (1/36)   | 12% (12/100)     |          |
| Always                         | 31% (42/136)     | 22% (8/36)  | 34% (34/100)     |          |
| Worried about getting HIV      |                  |             |                  |          |
| Not at all worried             | 59% (80/136)     | 72% (26/36) | 54% (54/100)     | 0.015    |
| Somewhat worried               | 13% (17/136)     | 14% (5/36)  | 12% (12/100)     |          |
| Very worried                   | 28% (38/136)     | 11% (4/36)  | 34% (34/100)     |          |
| No response/decline to answer  | 1% (1/136)       | 3% (1/36)   | 0% (0/100)       |          |
| Current risk reduction behavioursa |                |             |                  |          |
| Nothing                        | 15% (2/136)      | 3% (1/36)   | 1% (1/100)       | 0.46     |
| Abstinence (no sexual activity) | 10% (13/136)     | 25% (9/36)  | 4% (4/100)       | 0.001    |
participants rated injectable product attributes as highly acceptable (Figure 1). Acceptability ratings remained similar over time. Few participants reported rash or other side effects, but 56% to 67% reported pain with injection, with non-significant differences over time and between arms. However, fewer than 15% reported pain to be a little, somewhat or very unacceptable at week 28 or 44.

Most participants (79%) reported at least one injection site reaction (ISR) up to their fourth injection at week 28, and 50% reported at least one ISR during injections five to six which occurred between week 28 and 44. The median number of ISRs for those reporting them was five to six, with as many as 18 different adverse events reported by at least one participant.

In FGDs, participants described initial fear of the injectable and variable experiences with pain over time. A US participant admitted:

Getting the shots was my fear. Everything else I was fine with, the staff, everything. The atmosphere was just calm and welcoming. But I am scared of needles. I am 30 years old and two years ago you could not even take a butterfly needle to try and draw my blood until my mother got there.

A Cape Town participant suggested that the pain experienced during her first injection almost prevented her from continuing:

I felt like not coming back again. When I had my first injection, my butt was painful the whole week and so I thought to myself I’m not going to come back.

### 3.3 | Clinical trial context

Participants reported strong agreement with altruistic reasons for participating in the trial; the most highly endorsed reasons were to help the community and/or scientists. Women, especially in African settings, strongly agreed that they were seeking new experiences. Access to medical tests were somewhat endorsed, whereas concern about HIV risk for themselves and payment for participation were less endorsed. (Summary scores included in Table 1). Similarly, fewer than 15% of women reported any study-related concerns.

In FGDs, women often described a complex decision-making process for trial participation. They weighed concerns about trial procedures and product use, as well as partner or family opposition, with personal benefits from monetary

#### Table 1. (Continued)

| | Overall (n = 136) | US (n = 36) | Africa (n = 100) | p-values |
|---|---|---|---|---|
| Have sex with only one partner | 74% (101/136) | 50% (18/36) | 83% (83/100) | <0.001 |
| Male/female condoms, one/all partners | 84% (114/136) | 72% (26/36) | 88% (88/100) | 0.04 |
| Get tested for HIV | 44% (60/136) | 42% (15/36) | 45% (45/100) | 0.84 |
| Other | 3% (4/136) | 8% (3/36) | 1% (1/100) | 0.46 |

*Multiple responses allowed.

**Figure 1. Acceptability of injectable attributes.**

*Among those who experienced any pain (n = 73 at Week 4, 68 at Week 28 and 66 at Week 44).*
reimbursements and access to HIV testing and other medical procedures, and to their families and communities in terms of new prevention products. The emphasis on these different factors could vary. While multiple women in the US and Cape Town sites agreed that initially they decided to participate “for the money,” most added that other factors were also important. Some described first becoming aware of these other health benefits during prior HIV prevention trial participation, like this US participant:

I feel like I am giving back to the community, like I am part of a group that helped find preventative methods for HIV. I was part of other research studies. But, it is true, the few extra dollars are a motivation.

Women in the Zimbabwe FGD, while also describing monetary and health-related reasons, were more likely than those in the US and South African FGDs to mention altruistic reasons for joining the trial.

I did not join for the sake of my life but for the sake of my fellows, such that even when I told my other relatives about it, they talked me out of it saying, ‘You will have side effects. You would die.’ and so forth. I gave them an example and said, ‘Isn’t it that when you were born, you were given those immunization injections? And she said, ‘Yes.’ And I then asked, ‘Where did they begin? You do not know where they started from, so it is just the same.’

### 3.4 Interest in using an injectable PrEP product

At baseline, 56% of US participants and 81% of African participants preferred using a bi-monthly injectable to other prevention methods, including daily oral pills, a vaginal ring or gel; interest increased in both regions over the study. At week 28, 79% of participants strongly endorsed the statement that they would “definitely use an injectable PrEP product for some time” if it were available in the future. Even more women (88%) strongly agreed that they would be “more interested in using an injectable if it was both for HIV and pregnancy prevention.” (Table 2). In a sensitivity analysis, there was no association between permanent discontinuation of the injectable and FIIP (data not shown.)

In longitudinal univariate models (Table 3), several of our theorized determinants, including acceptability of product

| Table 2. Prevention preferences at baseline and 28 weeks |
|---------------------------------------------------------|
| **Baseline prevention preference** (n = 136) (n = 36) (n = 100) 0.02 |**Overall** | **US** | **Africa** | **p-values** |
| No preference | 0% (0/136) | 0% (0/36) | 0% (0/100) |
| Bi-monthly injection | 74% (101/136) | 56% (20/36) | 81% (81/100) |
| Daily oral pill | 15% (20/136) | 25% (9/36) | 11% (11/100) |
| Vaginal ring | 4% (5/136) | 8% (3/36) | 2% (2/100) |
| Vaginal gel | 0% (0/136) | 0% (0/36) | 0% (0/100) |
| Other (e.g. implant, sterilization, IUD) | 7% (10/136) | 11% (4/36) | 6% (6/100) |

| **Follow-up prevention preference (week 28)** (n = 113) (n = 34) (n = 79) 0.001 | **Overall** | **US** | **Africa** | **p-values** |
| No preference | 0% (0/113) | 0% (0/34) | 0% (0/79) |
| Bi-monthly injection | 89% (101/113) | 74% (25/34) | 96% (76/79) |
| Daily oral pill | 10% (11/113) | 24% (8/34) | 4% (3/79) |
| Vaginal ring | 0% (0/113) | 0% (0/34) | 0% (0/79) |
| Vaginal gel | 1% (1/113) | 3% (1/34) | 0% (0/79) |
| Other | 0% (0/113) | 0% (0/34) | 0% (0/79) |

| **Week 28 Would Definitely Use Injection** (n = 112) (n = 32) (n = 80) 0.001 | **Overall** | **US** | **Africa** | **p-values** |
| A lot (disagree) | 4% (5/112) | 9% (3/32) | 3% (2/80) |
| Somewhat (disagree) | 0% (0/112) | 0% (0/32) | 0% (0/80) |
| A little (disagree) | 3% (3/112) | 6% (2/32) | 1% (1/80) |
| A little (agree) | 5% (6/112) | 13% (4/32) | 3% (2/80) |
| Somewhat (agree) | 9% (10/112) | 19% (6/32) | 5% (4/80) |
| A lot (agree) | 79% (88/112) | 53% (17/32) | 89% (71/80) |

| **Would be more interested …if it was for both HIV and pregnancy prevention** (n = 113) (n = 33) (n = 80) <0.001 | **Overall** | **US** | **Africa** | **p-values** |
| A lot (disagree) | 2% (2/113) | 3% (1/33) | 1% (1/80) |
| Somewhat (disagree) | 2% (2/113) | 6% (2/33) | 0% (0/80) |
| A little (disagree) | 1% (1/113) | 3% (1/33) | 0% (0/80) |
| A little (agree) | 3% (3/113) | 6% (2/33) | 1% (1/80) |
| Somewhat (agree) | 5% (6/113) | 15% (5/33) | 1% (1/80) |
| A lot (agree) | 88% (99/113) | 67% (22/33) | 96% (77/80) |
attributes and of physical experiences, altruistic and personal motivations for trial participation, and HIV risk perception, were associated with FIIP. US participants reported significantly lower levels of FIIP than African women (OR = 0.14, p < 0.001) and those on TMC 278 had lower FIIP than those in the placebo arm (OR = 0.42, p = 0.04).

In the longitudinal multivariate model, product attribute scores and being from a non-US site remained the strongest predictors of FIIP. For example, in the adjusted model, a one unit increase in product attribute score over time increased the odds that a participant shows higher versus lower levels of agreement with FIIP more than twofold (OR = 2.38, p = 0.004). Total ISR count, treatment arm, perceived risk and risk behaviours were not significantly associated with FIIP, when controlling for other factors in the multivariate model (Table 3).

### Table 3. Univariate and Multivariate model on Interest in Future Use of Injectable PrEP

| Parameter                          | Comparison                      | Univariate Results | Multivariate Results |
|------------------------------------|---------------------------------|--------------------|----------------------|
|                                   |                                 | OR  | LCL  | UCL  | p-values | OR  | LCL  | UCL  | p-values |
| Product attributes                 |                                 | 3.14 | 1.76 | 5.58 | <0.001   | 2.38 | 1.32 | 4.28 | 0.004    |
| Physical experiences               |                                 | 2.22 | 1.46 | 3.4  | <0.001   | 1.32 | 0.6  | 2.92 | 0.48     |
| Personal benefits                  |                                 | 1.52 | 1.14 | 2   | 0.004    | 1.04 | 0.72 | 1.48 | 0.87     |
| Altruism                           |                                 | 3.36 | 1.62 | 6.98 | 0.001    | 1.74 | 0.64 | 4.68 | 0.27     |
| Contraception use                  | Yes = 1 versus No = 0           | 1.24 | 0.62 | 2.48 | 0.54     | 1.34 | 0.64 | 2.84 | 0.45     |
| Condom use                         |                                 | 1.18 | 0.96 | 1.44 | 0.12     | 0.98 | 0.8  | 1.24 | 0.92     |
| Worried HIV                        |                                 | 2.26 | 1.4  | 3.64 | <0.001   | 1.54 | 0.84 | 2.8  | 0.17     |
| Treatment                          | Active = 1 versus Placebo = 0   | 0.42 | 0.18 | 0.96 | 0.04     | 0.56 | 0.22 | 1.44 | 0.23     |
| Region                             | US = 1 versus Africa = 0        | 0.14 | 0.08 | 0.3  | <0.001   | 0.26 | 0.1  | 0.66 | 0.005    |
| Total ISR count                    |                                 | 0.94 | 0.92 | 0.98 | <0.001   | 0.98 | 0.96 | 1.02 | 0.39     |

LCL, lower confidence limit; OR, odds ratio; UCL, upper confidence limit.

#### DISCUSSION

Women’s challenges adhering to daily oral and vaginal PrEP within earlier clinical trials [14–16], and their relatively slow uptake of oral PrEP in service delivery settings [3,27] underscore the need for alternative PrEP delivery modes. As new HIV prevention approaches move through clinical trial research, it is important to assess what features of these products are acceptable – even desirable, and for whom [28].

Several studies in African settings that assessed preferences among hypothetical or placebo PrEP products suggested that women’s acceptability of injectable products would be high, but that product choice and use patterns would also be shaped by individual and social context and geographies [28,29]. Although a decision was made not to further evaluate TMC 278 LA as a prevention agent, in part due to requirements for cold-chain storage, this study provides one of the first opportunities to examine acceptability of an injectable PrEP product among a geographically diverse group of women using an active product. Its lessons may further complement those of another LAI PrEP product, Cabotegravir LA, which recently completed a phase 2 trial (HPTN 077) and is currently being evaluated among women in Africa and men in multiple settings. Like TMC 278, Cabotegravir LA is administered on a two-month schedule, but does not require cold storage.

First, in the study, women’s acceptability of the injectable was high. In both the US and African contexts, women preferred an injectable over daily pills and vaginal rings or gel; this preference increased over time as women’s experience with the product increased. It is noteworthy that participants’ attitudes towards product attributes, including receiving two injections – one in each buttck every two-months, was a stronger predictor of future interest in use than were their experiences with pain and other side effects. These findings are similar to acceptability data recently presented from a phase 2 trial of Cabotegravir LA (CAB LA) injectable (HPTN 077) [30] and a qualitative sub-study of ÉCLAIR, a phase 2 trial of CAB LA in MSM, which found overall high levels of acceptability, despite frequent but variable experiences of pain [31]. As additional long-acting PrEP modalities like implants and antibodies move through clinical trial research [32], there is an opportunity to further assess how participants understand and experience product features and the relative trade-offs they would consider in choosing and using a PrEP product.

Second, future interest in use of an injectable PrEP was significantly higher among African than US participants. This is not surprising, however, when considering regional differences in HIV prevalence. Indeed, almost half of African, but only one-quarter of US participants perceived moderate to high HIV risk and reported low levels of consistent condom use. Nevertheless, US women of colour – especially in the north-east and south have increased risk of acquiring HIV [33]. While PrEP awareness among US women remains low [4,34], community-based studies have identified a strong interest in PrEP use among US women [35–37] and globally [32], once women know about these prevention strategies.

The use of injectables for pregnancy prevention has increased dramatically in parts of eastern and Southern Africa [38]. In 2015, injectables accounted for about 5% of contraceptive use globally, but upwards of 25% to 30% in parts of SSA [23]. Women like the freedom from having to remember daily use and discretion afforded by injectable contraception.


5 | CONCLUSIONS

Although TMC 278 is not moving forward, this acceptability study provides valuable lessons for the successful introduction of future PrEP products more broadly. In this study, both US and African women reported an injectable PrEP product – TMC 278 LA – as highly acceptable and preferable to other new prevention products. Future interest in use was stronger among African than US women, who perceived higher levels of HIV risk. Women’s attitudes towards product attributes, influenced future interest in use more than pain experienced.

Given women’s and girls’ continuing burden of HIV infection globally and the need for – but challenges to achieving high levels of oral PrEP adherence, the development of a LAI PrEP or MPT product would provide an important new prevention tool.

AUTHORS’ AFFILIATIONS

1FHI 360, Durham, NC, USA; 2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 3Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa; 4University of Zimbabwe, Harare, Zimbabwe; 5Columbia University, New York, NY, USA; 6Rutgers New Jersey Medical School, Newark, NJ, USA.

COMPETING INTEREST

The authors declare no competing interests.

AUTHORS’ CONTRIBUTIONS

EET contributed to the design of acceptability measures and analyses and was primary author of final paper. SL and SZZ led statistical analyses. SP implemented quantitative data analysis. MA, PM and JS contributed to data collection and/or analysis of qualitative data. JJ, LGB, SS, JP and NS contributed to overall design and implementation of the study. All authors provided substantive review and comments leading to final manuscript.

ACKNOWLEDGEMENTS

We sincerely thank the participants and the following study site staff for their support: Emavundleni CRS in Cape Town, South Africa; Spilhaus CRS in Harare, Zimbabwe; Bronx Prevention Center CRS in Bronx, New York; and Rutgers, New Jersey Medical School CRS in Newark, New Jersey.

FUNDING

Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Numbers UM1AI066819, UM1AI068613 and UM1AI068617. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. HPTN 076 Study Team acknowledges the trial regulatory sponsor, PATH Drug Solutions, as well as the Bill & Melinda Gates Foundation and Janssen Pharmaceuticals, Inc.

REFERENCES

1. UN Women. Facts and figures: HIV and AIDS. New York, NY: UN Women. 2018.
2. Garlinkel DB, Alexander KA, McDonald-Mosley R, Willie TC, Decker MR. Predictors of HIV-related risk perception and PrEP acceptability among young adult female family planning patients. AIDS Care. 2017;29(6):751–8.
3. Aaron E, Blum C, Seidman D, Hoyt MJ, Simone J, Sullivan M, et al. Optimizing delivery of HIV preexposure prophylaxis for women in the United States. AIDS Patient Care STDs. 2018;32(1):16–23.
4. Flash CA, Dale SK, Krakower DS. Pre-exposure prophylaxis for HIV prevention in women: current perspectives. Int J Womens Health. 2017;9:391–401.
5. Corneli A, Wang M, Agot K, Ahmed K, Lombaard J, Van Damme L, et al. Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP. J Acquir Immune Defic Syndr. 2014;67(5):555–63.
6. Greene E, Batona G, Hallad J, Johnson S, Neema S, Tolley EE. Acceptability and adherence of a candidate microbicide gel among high-risk women in Africa and India. Cult Health Sex. 2010;12(7):739–54.
7. Foner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koecklin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973–83.
8. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangji J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.

9. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.

10. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–33.

11. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10031):53–60.

12. Molina JM, Capitant C, Spire B, Plaux G, Cotte L, Charreau I, et al. On-Demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.

13. Van Damme L, Cornel A, Ahmed K, Agot K, Lombard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.

14. Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, et al. Fem-Pro: adherence patterns and factors associated with adherence to a daily oral study drug for pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2014;66(3):324–31.

15. Marrazzo JM, Ramjee G, Richardson BA, Gomot N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.

16. Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–32.

17. Nel A, Bekker LG, Bukusi E, Hellstrom E, Kotze P, Louw C, et al. Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in Sub-Saharan Africa. PLoS One. 2016;11:e0147743.

18. Amico KR, Marcus JL, McMahan V, Liu A, Koester KA, Goicoechea P, et al. Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr. 2005;39(3):359–70.

19. Tolley E, Friedland B, Gafos M, Agot K, Van Damme L, Woodsong C, et al. Socio-economic and behavioral factors influencing choice, adherence and success of microbicide formulations. In: Das Neve D, Sarmento B, editors. Drug delivery and development of anti-HIV microbicides. Singapore: Pan Stanford Publishing; 2014. p. 569–628.

20. van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, et al. Acceptability of Long-Acting Injectable Cabotegravir (CALB LA) in HIV-Uninfected Individuals: HPTN 077 (OA05.01). HIV R4P; Tuesday, October 23, 2018; Madrid, Spain 2018.

21. Kerrigan D, Mantsoe A, Grant R, Markowitz M, Defechereux P, La Mar M, et al. Expanding the menu of HIV prevention options: a qualitative study of long-acting injectable cabotegravir as PrEP in the context of a Phase II trial in the United States. AIDS Behav. 2018;22(11):3540–9.

22. HIV.gov. What are long-acting HIV prevention tools? 2019 [cited 2019 Jul 20]. Available from: https://www.hiv.gov/hiv-basics/hiv-prevention/potential-future-options/long-acting-prep

23. Hodder SL, Justman J, Hafey DL, Adimora AA, Fogel CI, Golin CE, et al. Challenges of a hidden epidemic: HIV prevention among women in the United States. J Acquir Immune Defic Syndr. 2010;55 Suppl 2:569–73.

24. Rubstova A, Wingood GM, Dunkle K, Camp C, DiClemente RJ. Young adult women and correlates of potential adoption of pre-exposure prophylaxis (PrEP): results of a national survey. Curr HIV Res. 2015;11(7):543–8.

25. Wingood GM, Dunkle K, Camp C, Patel S, Painter JE, Rubstova A, et al. Racial differences and correlates of potential adoption of pre-exposure prophylaxis; results of a national survey. J Acquir Immune Defic Syndr. 2013;63 Suppl 1:S59–101.

26. Auerbach JD, Kinsky S, Brown G, Charles V, Knowledge, attitudes, and like-lihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDS. 2015;29(2):102–10.

27. Gogaraju L, Experton LS, Praschan NC, Warren-jeanpiere L, Young MA, Kassaye S. Women want pre-exposure prophylaxis but are advised against it by their HIV-positive counterparts. J AIDS Clin Res. 2015;6(11):1–10.

28. Ross J, Hardee K. Access to contraceptive methods and prevalence of use. J Biosoc Sci. 2013;45(6):761–78.

29. Tolley EE, McKenna K, Mackenzie C, Ngabo F, Munyambanza E, Arcara J, et al. Preferences for a potential longer-acting injectable contraceptive: perspectives from women, providers, and policy makers in Kenya and Rwanda. Glob Health Sci Pract. 2014;2(2):182–94.

30. Chin-Quee D, Brett J, Malkin M, Nduna MM, Otterness C, Jumbe L, et al. Building on safety, feasibility, and acceptability: the impact and cost of community health worker provision of injectable contraception. Glob Health Sci Pract. 2013;1(2):316–27.

31. McKenna K, Arcara J, Rademacher KH, Mackenzie C, Ngabo F, Munyambanza E, et al. Policy and programmatic considerations for introducing a longer-acting injectable contraceptive: perspectives of stakeholders from Kenya and Rwanda. Glob Health Sci Pract. 2014;2(4):459–71.

32. Siedner MJ, Hettema A, Hughey A, Oldenburg CE, Kohler S, Barnighausen K, et al. Preference for injectable over oral HIV pre-exposure prophylaxis in public-sector primary-care clinics in Swaziland. AIDS. 2013;27(11):1541–2.

33. Weinrib R, Minnis A, Agot K, Ahmed K, Owino F, Manenzhe K, et al. End-users product preference across three multipurpose prevention technology delivery forms: baseline results from young women in Kenya and South Africa. J Int AIDS Soc. 2018;22(1):133–45.

34. Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014;59 Suppl 1:S55–60.

35. Colfax G, Buchbinder S, Vamshidar G, Celum C, McKirnan D, Neidj J, et al. Motivations for participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2005;39(3):359–64.

36. Chin LJ, Berenson JA, Klitzman RL. Typologies of Altruistic and Financial Motivations for Research Participation. J Empir Res Hum Res Ethics. 2016;11(4):299–310.

37. Macphail C, Delany-Morette S, Mayaud P. ‘It’s not about money, it’s about my health’: determinants of participation and adherence among women in an HIV-HSV2 prevention trial in Johannesburg, South Africa. Patient Prefer Adher. 2012;6:577–89.

38. Cowan FM, Delany-Morette S, Sanders EJ, Mugo NR, Guedou FA, Alary M, et al. PrEP implementation research in Africa: what is new? J Int AIDS Soc. 2016;19(7 Suppl 6):21101.